Back
Corporate News
Alivus Life Sciences reports Rs 1,601 million net profit, revenue up 6.4% year-over-year
30-Jul-2026, 09:30
Alivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, announced a net profit after tax of Rs 1,601 million for the first quarter ended June 30, 2026, a 31.8% year-over-year increase, alongside revenue from operations of Rs 6,404 million, up 6.4% year-over-year, driven by a 26.5% year-over-year growth in its non-GPL business. The company reported earnings before interest, taxes, depreciation, and amortization of Rs 2,341 million, a 29.1% year-over-year increase, with margins at 36.6%, and held cash and cash equivalents of Rs 8,802 million as of June 30, 2026.
Alivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, announced a net profit after tax of Rs 1,601 million for the first quarter ended June 30, 2026, a 31.8% year-over-year increase, alongside revenue from operations of Rs 6,404 million, up 6.4% year-over-year, driven by a 26.5% year-over-year growth in its non-GPL business. The company reported earnings before interest, taxes, depreciation, and amortization of Rs 2,341 million, a 29.1% year-over-year increase, with margins at 36.6%, and held cash and cash equivalents of Rs 8,802 million as of June 30, 2026.